Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.
This activity is supported by an educational grant from Genomic Health, Inc.
Release Date: December 31, 2017
Expiration Date: December 31, 2018
Media: Internet - based
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™ features a summary of clinical evidence guiding the treatment of patients with breast cancer. Topics include the utility of gene expression assays for making decisions about adjuvant chemotherapy for patients with hormone receptor‒positive, HER2-negative breast cancer; current therapeutic options for patients with early-stage and metastatic HER2-positive breast cancer, including the management of brain metastases; and emerging therapies for BRCA-mutated and/or triple-negative breast cancer, such as poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors. This educational activity incorporates didactic reviews of key data accompanied by short video interviews with experts in the field, who share their perspectives on current treatment paradigms, practical patient management insights, and evolving prospects for the future.
This activity is supported by an educational grant from Genomic Health, Inc.
Instructions for This Activity and Receiving Credit
|
This educational activity is directed toward healthcare professionals who practice primarily outside of the United States. It is specifically designed for medical oncologists and other healthcare professionals (eg, physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants) involved in the treatment and management of patients with breast cancer.
At the conclusion of this activity, you should be better prepared to:
Faculty
Thomas Bachelot, MD, PhD
Director, Breast Cancer Unit
Centre Lèon Bèrard
Lyon, FranceKingdom
Disclosure: Grant/Research Support: AstraZeneca, Pfizer; Consultant/Advisory Board: AstraZeneca, Roche, Pfizer, Novartis
Nicholas Turner, MD, PhD
Academic Consultant
Medical Oncologist
Biomedical Research Centre
The Royal Marsden NHS Foundation Trust
The Institute of Cancer Research
London, United Kingdom
Disclosure: Grant/Research Support: AstraZeneca, Pfizer, Roche; Consultant/Advisory Board: AstraZeneca, Pfizer, Roche, Novartis, Lilly, G1 Therapeutics, H3 Biomedicine, Synthon
Andrew Tutt, MD, PhD
Professor in Oncology and Director of the Breast Cancer Now Research Unit
King’s College London
Head of the Division of Breast Cancer Research and Professor of Breast Oncology
The Institute of Cancer Research
London, United Kingdom
Disclosure: Grant/Research Support: Myriad Genetics‒ Research costs for TNT trial; Consultant/Advisory Board: Vertex Pharmaceuticals, AstraZeneca; Shareholder: Rewards to inventors scheme Institute of Cancer Research
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
PER Pulse Recap (1 of 3)
Insight From Nicholas Turner, MD, PhD – PER Pulse™ Recap: Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™ is a continuing medical education (CME)-certified interactive online activity released in December 2017. In this activity, expert faculty Thomas Bachelot, MD, PhD; Nicholas Turner, MD, PhD; and Andrew Tutt, MD, PhD, discuss clinical evidence guiding the treatment of patients with breast cancer and share their perspectives on current therapeutic paradigms, practical patient management strategies, and prospects for the future.
This first of 3 PER Pulse™ Recaps summarizing the online activity focuses on the evolving role of gene expression assays for guiding decisions about adjuvant therapy for hormone receptor–positive (HR+) breast cancer. Below are some highlights from the activity featuring Dr. Turner:
“Standard clinical predictors, such as tumor burden, and genomic predictors both provide complimentary information, and the very best way to use these tests is to integrate that altogether to get the very best picture of prognosis.”
— Nicholas Turner, MD, PhD
PER Pulse Recap (2 of 3)
Insight From Thomas Bachelot, MD, PhD – PER Pulse™ Recap: Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™ is a CME-certified interactive online activity released in December 2017. In this activity, expert faculty Thomas Bachelot, MD, PhD; Nicholas Turner, MD, PhD; and Andrew Tutt, MD, PhD, discuss clinical evidence guiding the treatment of patients with breast cancer and share their perspectives on current therapeutic paradigms, practical patient management strategies, and prospects for the future.
This second of 3 PER Pulse™ Recaps summarizing the online activity focuses on evolving paradigms for HER2-positive (HER2+) early-stage breast cancer and current standards for HER2+ metastatic breast cancer (MBC), including the management of brain metastases. Below are some highlights from the activity featuring Dr. Bachelot:
“Patients with [HER2+] brain metastases tend to live very long; not as long, but nearly as long as a patient without brain metastases.”
— Thomas Bachelot, MD, PhD
PER Pulse Recap (3 of 3)
Insight from Andrew Tutt, MD, PhD – PER Pulse™ Recap: Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™ is a CME-certified interactive online activity released in December 2017. In this activity, expert faculty, Thomas Bachelot, MD, PhD; Nicholas Turner, MD, PhD; and Andrew Tutt, MD, PhD, discuss clinical evidence guiding the treatment of patients with breast cancer and share their perspectives on current therapeutic paradigms, practical patient management strategies, and prospects for the future.
This third of 3 PER Pulse™ Recaps summarizing the online activity focuses on emerging therapies for BRCA-mutated and triple-negative breast cancers (TNBCs). Below are some highlights from the activity featuring Dr. Tutt:
“[For] patients who have genomically unstable, potentially homologous recombination–deficient forms of triple-negative breast cancer, I think it is very promising targeting those aberrations in the DNA damage response with PARP inhibition, potentially in combination with other DNA damage response–targeting therapies, perhaps in combination with immunotherapy.”
— Andrew Tutt, MD, PhD
SUN | MON | TUES | WED | THURS | FRI | SAT |
1 | 2 | |||||
3 | 4 | 5 | 6 | 7 | 8 | 9 |
10 | 11 | 12 | 13 | 14 | 15 | 16 |
17 | 18 | 19 | 20 | 21 | 22 | 23 |
24 | 25 | 26 | 27 | 28 |